Klow Blend (TB-500/10MG-BPC-157/10MG-GHK/50MG-KPV/10MG)

KLOW Peptide Blend Evidence

KLOW is a precision-formulated peptide blend combining GHK-Cu, KPV, BPC-157, and TB500, designed to synergistically support cellular repair, inflammation control, and tissue regeneration.

Cellular Repair & Tissue Regeneration

• GHK-Cu: Stimulates collagen, elastin, and GAG synthesis; promotes angiogenesis and fibroblast activation; accelerates wound healing in skin, bone, GI mucosa, and other tissues; upregulates pro-repair genes and downregulates pro-inflammatory/tissue-destructive genes.^[1–6]
• BPC-157: Pleiotropic healing across skin, muscle, tendon, ligament, nerve, and GI tissue; supports angiogenesis, modulates growth-factor pathways, and facilitates rapid resolution of vessel constriction/clot formation; broad wound-healing gene modulation.^[7–8]
• TB500 (thymosin β4): Actin sequestration, cell migration, and angiogenesis to accelerate repair and reduce fibrosis (established in preclinical/translational literature).

Inflammation Control

• GHK-Cu: Suppresses TNF-α/IL-6, inhibits NF-κB and p38 MAPK, reduces oxidative stress; restores MMP/TIMP balance; mitigates inflammatory cell infiltration and supports mucosal/epithelial healing via SIRT1/STAT3 and TGFβ1/Smad2/3 pathways in colitis and pulmonary fibrosis models.^[3,9–12]
• BPC-157: Anti-inflammatory and cytoprotective across multiple organs with favorable safety in preclinical work; supports tissue homeostasis during injury/repair.^[7–8]
• KPV (Lys-Pro-Val): Melanocortin-derived tripeptide that inhibits pro-inflammatory cytokines and supports epithelial barrier function (established in literature).

Synergistic Mechanisms

• GHK-Cu: Drives tissue remodeling, angiogenesis, and anti-inflammatory gene programs.^{[1–6,9–12]}
• BPC-157: Accelerates wound closure, supports angiogenesis, modulates inflammation.^[7–8]
• KPV: Targets cytokine suppression and epithelial barrier integrity (mechanism established).
• TB500: Enhances cell migration/angiogenesis and reduces fibrosis (mechanism established).

References

1. Pickart L, Margolina A. Int J Mol Sci. 2018;19(7):E1987.
2. Pickart L. J Biomater Sci Polym Ed. 2008;19(8):969-988.
3. Pickart L, Vasquez-Soltero JM, Margolina A. Biomed Res Int. 2015;2015:648108.
4. Pickart L, Vasquez-Soltero JM, Margolina A. Biomed Res Int. 2014;2014:151479.
5. Wang X, Liu B, Xu Q, et al. Wound Repair Regen. 2017;25(2):270-278.
6. Lee S, Lee SM, Lee SH, et al. Acta Biomater. 2023;172:159-174.
7. Seiwerth S, Milavic M, Vukojevic J, et al. Front Pharmacol. 2021;12:627533.
8. Józwiak M, Bauer M, Kamysz W, Kleczkowska P. Pharmaceuticals. 2025;18(2):185.
9. Ma WH, Li M, Ma HF, et al. Life Sci. 2020;241:117139.
10. Park JR, Lee H, Kim SI, Yang SR. Oncotarget. 2016;7(36):58405-58417.
11. Pickart L, Vasquez-Soltero JM, Margolina A. Oxid Med Cell Longev. 2012;2012:324832.
12. Mao S, Huang J, Li J, et al. Front Pharmacol. 2025;16:1551843.

All COA’s avail upon request by email info@truformlabs.com.

Storage & Handling (Research Use)

• Lyophilized (dry) vials: Store sealed at −20 °C (long-term), desiccated and protected from light. Short-term (≤2–3 weeks) at 2–8 °C is acceptable.
• After reconstitution: Store at 2–8 °C and use within 7 days, or aliquot into sterile vials and freeze at −20 °C for up to 3 months.
• Avoid freeze–thaw: Prepare small aliquots to prevent repeated freeze–thaw cycles.
• Solvent: Reconstitute per protocol (e.g., sterile saline/bacteriostatic water). For GHK-Cu–containing blends, avoid strong chelators (e.g., EDTA) that can disrupt the copper complex.
• Handling: Keep solutions on ice during use; discard any unused thawed aliquots.
• Labeling: Clearly mark concentration, solvent, and preparation date on all aliquots.

General guidance for peptide blends; follow your lab’s SOPs and product-specific stability data when available.